Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset

INTRODUCTION: The phase 3 RELAY global study (NCT02411448) revealed significant improvement in progression-free survival (PFS) with ramucirumab plus erlotinib (RAM + ERL) compared with placebo plus ERL (PL + ERL) in untreated EGFR-mutated metastatic NSCLC (hazard ratio [HR] = 0.59 [95% confidence in...

Descripción completa

Detalles Bibliográficos
Autores principales: Nishio, Kazuto, Seto, Takashi, Nishio, Makoto, Reck, Martin, Garon, Edward B., Sakai, Kazuko, Goto, Koichi, Kato, Terufumi, Nakanishi, Yoichi, Takahashi, Toshiaki, Yamamoto, Nobuyuki, Kiura, Katsuyuki, Ohe, Yuichiro, Tamura, Tomohide, Visseren-Grul, Carla, Frimodt-Moller, Bente, Hozak, Rebecca R., Wijayawardana, Sameera R., Zimmermann, Annamaria, Homma, Gosuke, Enatsu, Sotaro, Nakagawa, Kazuhiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474372/
https://www.ncbi.nlm.nih.gov/pubmed/34590023
http://dx.doi.org/10.1016/j.jtocrr.2021.100171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8474372/
https://www.ncbi.nlm.nih.gov/pubmed/34590023
http://dx.doi.org/10.1016/j.jtocrr.2021.100171

Ejemplares similares